Hemostatic Gauze, Chitosan-Based

The Defense Health Agency's Medical Logistics Division, in collaboration with the Defense Logistics Agency Troop Support Medical Prime Vendor Program, is seeking qualified suppliers to establish a Qualified Suppliers Listing for Chitosan-Based Hemostatic Gauze products. This initiative aims to identify vendors capable of providing sterile, FDA-cleared, and non-latex hemostatic gauze with specific features such as x-ray detectable stripes, individual packaging, and instructions for use, primarily for military medical facilities and operational units. The process involves vendors registering in the DAPA Management System, submitting detailed product documentation, and demonstrating compliance with requirements including TAA country-of-origin standards, non-latex composition, and sterilization validation. The anticipated establishment of the Qualified Suppliers Listing is around November 1, 2024, with subsequent invitations for vendors to submit pricing and supporting documentation to qualify for Incentive Agreements, which are not contractual commitments but facilitate product standardization and procurement. The estimated annual demand for this product line is approximately 9,542 units, representing a sales volume of about $364,457. Vendors must meet specific technical and regulatory criteria, including providing detailed product specifications, packaging images, and certification evidence, to be considered. The overall goal is to streamline the procurement of high-quality, compliant hemostatic gauze for military medical use, ensuring readiness and operational effectiveness across various military branches.